Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index; 57 of the 135 sources its claims cite were checked for support.
Abstract
The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset dementia. The diagnosis of bvFTD remains challenging because of the limited accuracy of neuroimaging in the early disease stages and the absence of molecular biomarkers, and therefore relies predominantly on clinical assessment. BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders. To date, ∼50% of patients with bvFTD receive a prior psychiatric diagnosis, and average diagnostic delay is up to 5-6 years from symptom onset. It is also not uncommon for patients with primary psychiatric disorders to be wrongly diagnosed with bvFTD. The Neuropsychiatric International Consortium for Frontotemporal Dementia was recently established to determine the current best clinical practice and set up an international collaboration to share a common dataset for future research. The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment. A systematic literature search with a narrative review was performed to determine all bvFTD-related diagnostic evidence for the following topics: bvFTD history taking, psychiatric assessment, clinical scales, physical and neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural neuroimaging, functional neuroimaging, CSF and genetic testing. For each topic, responsible team members proposed a set of minimal requirements, optimal clinical recommendations, and tools requiring further research or those that should be developed. Recommendations were listed if they reached a ≥ 85% expert consensus based on an online survey among all consortium participants. New recommendations include performing at least one formal social cognition test in the standard neuropsychological battery for bvFTD. We emphasize the importance of 3D-T1 brain MRI with a standardized review protocol including validated visual atrophy rating scales, and to consider volumetric analyses if available. We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD when normal, whereas non-specific regional metabolism abnormalities should not be over-interpreted in the case of a psychiatric differential diagnosis. We highlight the potential role of serum or CSF neurofilament light chain to differentiate bvFTD from primary psychiatric disorders. Finally, based on the increasing literature and clinical experience, the consortium determined that screening for C9orf72 mutation should be performed in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
Overview
CoChat Summary
TL;DR
This consensus review from the Neuropsychiatric International Consortium for Frontotemporal Dementia summarizes evidence and expert recommendations for distinguishing behavioural variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPD). It recommends formal social cognition testing, standardized 3D-T1 MRI review, cautious FDG-PET interpretation, consideration of neurofilament light chain, and C9orf72 screening in possible/probable bvFTD or suspected cases with strong psychiatric features.
Key findings
- bvFTD is frequently misdiagnosed: around 50% of patients receive a prior psychiatric diagnosis, average diagnostic delay is up to 5–6 years from symptom onset, possible bvFTD criteria had poor specificity (27%) in a mixed neuropsychiatric cohort, standard MRI sensitivity was 70%, and FDG-PET specificity was 68% because of frequent non-specific abnormalities in PPD.
- New or emphasized recommendations include at least one formal social cognition test in the standard neuropsychological battery for bvFTD; 3D-T1 brain MRI with a standardized review protocol and validated visual atrophy rating scales, considering volumetric analyses if available; FDG-PET to support exclusion when normal, while non-specific regional hypometabolism should not be over-interpreted in a psychiatric differential diagnosis; consideration of serum or CSF neurofilament light chain (NfL) where reference values are available; and C9orf72 screening in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
- Biomarker evidence cited: CSF NfL discriminated bvFTD from PPD with an AUC of 0.93 in a study of 22 bvFTD and 25 PPD patients; plasma NfL showed AUCs of 0.89–0.94 against schizophrenia, depression, and bipolar disorder, and 0.83 in a larger study of 66 bvFTD and 34 PPD patients; CSF NfL discriminated FTD mutation carriers from controls with an AUC of 0.99.
- Clinical scales and cognitive tests have mixed utility: the Frontal Behavioral Inventory overall score does not distinguish bvFTD from PPD, but a positive FBI subscale score >12 was indicative of bvFTD in late-onset behavioural changes; MMSE was unsuccessful for discrimination; MoCA had 88% classification accuracy for brief cognitive screening but uncertain value against PPD; the Institute of Cognitive Neurology Frontal Screening may have discriminatory power; and a meta-analysis indicated social cognition impairment in bvFTD is more severe than in major psychiatric and developmental disorders.
Methods
- Systematic literature search in Medline (PubMed) and Embase, completed September 2017, retrieving articles from 1992 to 2017, with relevant later references allowed; topics included bvFTD history taking, psychiatric assessment, clinical scales, physical/neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural and functional neuroimaging, CSF, and genetic testing.
- Each topic was assigned to two to three NIC-FTD members based on expertise; teams reviewed abstracts and proposed minimal requirements, clinical recommendations, and tools requiring further research; an in-person meeting was held in Sydney on 13 November 2018, followed by two rounds of draft review and teleconferences.
- Final consensus was obtained through an online survey of all co-authors, with ≥85% approval required to include recommendations.
Limitations
- The paper states that diagnostic methods useful for distinguishing bvFTD from other dementias, such as clinical scales and cognitive tests, do not fare as well against PPD; some patients remain diagnostically ambiguous despite optimal clinical investigation, so longitudinal follow-up often becomes the diagnostic arbiter until pathology is available; non-progressive bvFTD phenocopy cases are particularly challenging, with small sample studies and some showing no FTLD pathological changes.
- The paper states a need for better prognostic tools; CSF biomarkers require study in larger, ideally pathologically and/or genetically confirmed bvFTD cohorts; volumetric and machine-learning MRI methods lack replication and prospective validation at the individual subject level; and many social cognition instruments lack normative data and transcultural adaptation.
- Evident from the text: the recommendations are consensus-based (≥85% expert approval) rather than prospectively validated, and many cited diagnostic accuracy estimates come from small or single studies; the systematic search ended in September 2017, with later references added non-systematically.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Valid · 11 Not valid · 43 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients with FTD secondary to the C9orf72 mutation can present with heterogeneous neuropsychiatric phenotypes (such as lateonset psychosis or mania) without family history, sometimes several years prior to onset of more typical bvFTD features (Ducharme et al. , 2017).”
What the sources say
- Supportedcites Ducharme et al., 2017 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Mild Behavioral Impairment Checklist is a more specific tool to measure later-life behavioural changes that can be the harbinger of dementia (Ismail et al. , 2017); however, it does not facilitate the differentiation of PPD from bvFTD.”
What the sources say
- Supportedcites Ismail et al., 2017 source
The citation is attached to the first clause, which describes the MBI-C as a tool for measuring later-life behavioural changes that may precede dementia. The Discussion says it was created to measure behavioural changes in older adults that might precede dementia. The subsequent statement about differentiating PPD from bvFTD is not attributed to this source by the citation placement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“DAPHNE, a recently developed informant-based behavioural inventory with 10 items based on the 2011 bvFTD international consensus diagnostic criteria, demonstrated an ability to distinguish bvFTD from bipolar disorder (Boutoleau-Bretonniere et al. , 2015).”
What the sources say
- Supportedcites Boutoleau-Bretonniere et al., 2015 source
The Results (Validation of the DAPHNE Scale; page not provided) state that DAPHNE differentiated bvFTD from the comparison groups, including patients with bipolar disorder. The Abstract (Objective) describes a ten-item inventory adapted from Rascovsky’s criteria, and the Methods describe its administration to caregivers. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“On the IFS, however, patients with bvFTD scored significantly worse on several sub-items than subjects with major depression and bipolar disorder (Fiorentino et al. , 2013).”
What the sources say
- Partly supportedcites Fiorentino et al., 2013 sourceExperimental — accuracy not yet measured
The Results report significantly lower bv-FTD scores than depression scores on five IFS subtests. The Methods identify the comparison group as patients with unipolar depression; the cited study does not support the claim about bipolar disorder. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Major consensus dementia investigation guidelines all recommend structural brain imaging as part of the investigation of bvFTD (Knopman et al. , 2001; Filippi et al. , 2012; Soucy et al. , 2013).”
What the sources say
- Not checked — no full text of the sourcecites Knopman et al. , 2001 source
- Supportedcites Filippi et al. , 2012 source
The Background states that European, UK and US guidelines recommend structural imaging when assessing suspected dementia. The paper’s Recommendations for structural MRI call for structural imaging at least once in the diagnostic work-up, and its recommendations identify frontal and temporal atrophy as findings to assess in FTD. (LLM, conf=0.91)
- Partly supportedcites Soucy et al. , 2013 sourceExperimental — accuracy not yet measured
The CCCDTD4 recommendations (Table 1; page unavailable) say structural imaging is indicated for most people with cognitive impairment, but not required for all. The “Structural neuroimaging in memory clinics” section says MRI is preferred for detecting atrophy patterns in fronto-temporal dementias. The paper therefore supports imaging as relevant to investigating these dementias, but does not establish that all major consensus guidelines recommend it specifically for bvFTD. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims · 26 with their cited sources checked
Create a free account to see all 101 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the absence of molecular biomarkers, and when combined with the syndromic overlap with other neurodegenerative disorders and psychiatric disorders, a confirmed behavioral variant frontotemporal dementia (bvFTD) diagnosis is often difficult to achieve and heavily relies on brain imaging. 6”
From MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia (2021) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to its clinical and pathological heterogeneity and symptomatic overlap with other neurodegenerative diseases, such as Alzheimer’s disease (AD), and other non-neurodegenerative psychiatric disorders, the differential diagnosis of FTD remains challenging [2, 7–9].”
From A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the differentiation between FTD and non‐neurodegenerative disorders, several CSF studies showed an excellent performance of NfL for discriminating FTD from psychiatric disorders (AUC > 0.90) 56 , 71 , 75 and consequent perceived added clinical use for the physician.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, serum NfL has the highest diagnostic accuracy with AUC of up to 0.94 for differentiating FTD from primary psychiatric disorders.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The construct of social cognition, including emotion recognition, theory of mind, empathy, and moral reasoning, has been proven difficult to measure in clinical practice. 71”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Self-citationKok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationThe FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
Meeting of minds: the medial frontal cortex and social cognition
Amodio, D. M., & Frith, C. D. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1884 · Cited by 3,782
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Research works printed but not linked: 1
- Cerami, 2014, Optimized objective SPM analysis improves accuracy of [18F]FDG-PET imaging in dementia diagnosis, Eur J Neurol, 21, 303
Cited by
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
“Thus, as specified in current international recommendations 157 , measurement of NfL in CSF or blood could be used in practice for the differential diagnosis of bvFTD and PPD 158 , provided that validated thresholds could be defined.”
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citationThe use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“…encephalitis, chronic schizophrenia, alcohol related brain damage and late onset psychiatric disorders [137 – 139] may also be associated with patterns of frontal hypometabolism on FDG-PET and therefore FDG-PET should be used in combination with history and other examinations available [140 – 142].”
MethodFrontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citationCognitive Impairment in Older Adults
Pérez Palmer, N., Trejo Ortega, B., & Joshi, P. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.010 · Cited by 177
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Verde, F., Otto, M., & Silani, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.679199 · Cited by 152
Moguilner, S., Baez, S., Hernandez, H., Migeot, J., Legaz, A., Gonzalez-Gomez, R., Farina, F. R., Prado, P., Cuadros, J., Tagliazucchi, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03209-x · Cited by 128
“We focused on the Alzheimer disease and bvFTD because these conditions represent the most common late-onset and early-onset causes of dementia 38,39 .”
BackgroundShoaib, S., Ansari, M. A., Fatease, A. M. A., Safhi, A. Y., Hani, U., Jahan, R., Alomary, M. N., Ansari, M. N., Ahmed, N., Wahab, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030749 · Cited by 172
“Therefore, cognitive neuropsychological tests, brain (CT, MRI, and PET) scans, laboratory tests, and neurological and psychiatric evaluation may help in diagnosing dementias [11,12].”
BackgroundFrontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
“Absence of amyloid binding, because of its high negative predictive value, rules out AD in favour of other causes of dementia, such as bvFTD [153].”
BackgroundFluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122
Self-citationThe multifaceted role of neurofilament light chain protein in non-primary neurological diseases
Abu‐Rumeileh, S., Abdelhak, A., Foschi, M., D’Anna, L., Russo, M., Steinacker, P., Kühle, J., Tumani, H., Blennow, K., & Otto, M. (2022) · Brain · doi:10.1093/brain/awac328 · Cited by 132
Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Barker, M. S., Gottesman, R. T., Manoochehri, M., Chapman, S., Appleby, B. S., Brushaber, D., Devick, K. L., Dickerson, B. C., Domoto-Reilly, K., Fields, J. A., et al. (2022) · Brain · doi:10.1093/brain/awab365 · Cited by 106
“Second, insight or concern may be a key feature in discriminating bvFTD from psychiatric disorders, such that insight is generally reduced in the former and preserved in the latter.(63) Features such as a lack of insight or lack of concern, for which we have some evidence of clinical utility and specificity, should be…”
BackgroundSelf-citationNetwork structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia
Shafiei, G., Bazinet, V., Dadar, M., Manera, A. L., Collins, D. L., Dagher, A., Borroni, B., Sánchez‐Valle, R., Moreno, F., Laforce, R. J., et al. (2022) · Brain · doi:10.1093/brain/awac069 · Cited by 96
“Clinically, this is reflected by progressive cortical atrophy, which is a crucial biomarker for the diagnosis.(5,6) While there is”
BackgroundSelf-citationIncidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries
Logroscino, G., Piccininni, M., Graff, C., Hardiman, O., Ludolph, A. C., Moreno, F., Otto, M., Remes, A. M., Rowe, J. B., Seelaar, H., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5128 · Cited by 91
Self-citationYoung‐onset dementia diagnosis, management and care: a narrative review
Loi, S. M., Cations, M., & Velakoulis, D. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51849 · Cited by 112
Self-citationPrevalence, Structure, and Risk Factors for Mental Disorders in Older People
Петрова, Н. Н., & Khvostikova, D. A. (2021) · Advances in Gerontology · doi:10.1134/s2079057021040093 · Cited by 102
“, conducted a review of the approaches to differential diagnosis of the behavioral variant frontotemporal dementia (FTD, or Pick’s disease) and primary mental disorders unrelated to dementia [21].”
BackgroundLeroy, M., Bertoux, M., Skrobala, E., Mode, E., Adnet‐Bonte, C., Ber, I. L., Bombois, S., Cassagnaud, P., Chen, Y. S., Deramecourt, V., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00753-9 · Cited by 82
“Second, the positive diagnosis of bvFTD and its differentiation with primary psychiatric disorders is another diagnostic challenge [38] that is reflected by the increased time to presentation and time to diagnosis of the bvFTD variants as compared with the others [39, 40].”
ResultSelf-citationKatisko, K., Cajanus, A., Huber, N., Jääskeläinen, O., Kokkola, T., Kärkkäinen, V., Rostalski, H., Hartikainen, P., Koivisto, A. M., Hannonen, S., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326487 · Cited by 65
Quesque, F., Coutrot, A., Cox, S., de Souza, L. C., Báez, S., Cardona, J. F., Mulet‐Perreault, H., Flanagan, E. C., Neely‐Prado, A., Clarens, M. F., et al. (2022) · Neuropsychology · doi:10.1037/neu0000817 · Cited by 75
Self-citationPalermo, G., Mazzucchi, S., Vecchia, A. D., Siciliano, G., Bonuccelli, U., Azuar, C., Ceravolo, R., Lista, S., Hampel, H. J., & Baldacci, F. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02035-9 · Cited by 57
Self-citationUnravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions
van der Ende, E. L., Jackson, J. L., White, A. E., Seelaar, H., van Blitterswijk, M., & Swieten, J. C. V. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325377 · Cited by 63
Self-citationAdvances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
“71,90,91 However, normal NfL levels still do not rule out FTD.”
InfluentialSelf-citationThe 2022 Lady Estelle Wolfson lectureship on neurofilaments
Petzold, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15682 · Cited by 56
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50
Self-citationTsoukra, P., Velakoulis, D., Wibawa, P., Malpas, C. B., Walterfang, M., Evans, A. H., Farrand, S., Kelso, W. M., Eratne, D., & Loi, S. M. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20100266 · Cited by 50
Self-citationEratne, D., Loi, S. M., Li, Q., Stehmann, C., Malpas, C. B., Santillo, A., Janelidze, S., Cadwallader, C., Walia, N., Ney, B., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12549 · Cited by 46
“, Breathing Control as a treatment for Psychogenic Non-Epileptic Seizures, Melbourne Research Grant Support Scheme (2020), $44,346; (6) Rolfe, T.”
BackgroundInfluentialSelf-citationOlfactory dysfunction in frontotemporal dementia and psychiatric disorders: A systematic review
Carnemolla, S. E., Hsieh, J. W., Sipione, R., Landis, B. N., Kumfor, F., Piguet, O., & Manuel, A. L. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.08.002 · Cited by 46
Self-citationEratne, D., Kang, M. J., Malpas, C. B., Simpson, S., Lewis, C. C., Dang, C., Grewal, J. K., Coe, A., Dobson, H., Keem, M. H., et al. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231187312 · Cited by 41
“…performance of plasma NfL to distinguish bvFTD from PPD, supports the clinical use of a relatively easily accessible blood biomarker, to assist in this challenging, clinical distinction (Al Shweiki et al., 2019; Ducharme et al., 2020; Eratne et al., 2022b; Katisko et al., 2020; Ooi et al., 2022).”
BackgroundSelf-citationHazelton, J. L., Fittipaldi, S., Fraile-Vazquez, M., Sourty, M., Legaz, A., Hudson, A. L., Cordero, I. G., Salamone, P. C., Yoris, A., Ibañez, A., et al. (2023) · Cortex · doi:10.1016/j.cortex.2023.02.009 · Cited by 39
“Over the past decade, impairment in emotion recognition has been established as a characteristic diagnostic feature (Boeve et al., 2022; Ducharme et al., 2020).”
BackgroundSelf-citationWhat Do We Mean by Behavioral Disinhibition in Frontotemporal Dementia?
Magrath Guimet, N., Miller, B. L., Allegri, R. F., & Rankin, K. P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.707799 · Cited by 38
“On the other hand, we now know that many FTLD gene mutation carriers present with psychiatric manifestations years before meeting criteria for a bvFTD diagnosis (10, 13, 14), making this distinction of timing less definitively diagnostic.”
BackgroundNeurofilaments contribution in clinic: state of the art
Delaby, C., Bousiges, O., Bouvier, D., Fillée, C., Fourier, A., Mondésert, E., Nezry, N., Omar, S., Quadrio, I., Rucheton, B., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1034684 · Cited by 39
“Thus, according to recently published international recommendations (Ducharme et al., 2020), NfL measurement in CSF or blood could be used in practice for the differential diagnosis between FTD and SPD, as long as validated thresholds are available.”
BackgroundBolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36
“Blood NfL has already been implemented in the novel guidelines for differentiating FTD from non-degenerative primary psychiatric disorders [9, 25].”
Incidence and Prevalence of Frontotemporal Dementia: A Systematic Review and Meta-Analysis
Urso, D., Giannoni‐Luza, S., Brayne, C., Ray, N., & Logroscino, G. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.3307 · Cited by 55
The behavioral pattern of patients with frontotemporal dementia during the COVID-19 pandemic
Suzuki, M., Hotta, M., Nagase, A., Yamamoto, Y., Hirakawa, N., Satake, Y., Nagata, Y., Suehiro, T., Kanemoto, H., Yoshiyama, K., et al. (2020) · International Psychogeriatrics · doi:10.1017/s104161022000109x · Cited by 35
“Frontotemporal dementia (FTD) is known to have distinct clinical features from Alzheimer’s disease (AD), developing behavioral and language symptoms with relatively preserved memory function (Ducharme et al., 2020; Neary et al., 1998; Rascovsky et al., 2011).”
BackgroundSelf-citationPharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Le, C., & Finger, E. (2021) · CNS Drugs · doi:10.1007/s40263-021-00854-5 · Cited by 26
Eratne, D., Janelidze, S., Malpas, C. B., Loi, S. M., Walterfang, M., Merritt, A. H., Diouf, I., Blennow, K., Zetterberg, H., Cilia, B.-J., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211058684 · Cited by 33
“…people with established schizophrenia (even treatment-resistant or poor outcome), from progressive neurodegenerative disorders such as behavioural variant frontotemporal dementia, an oftenchallenging clinical distinction (Chan et al., 2014; Ducharme et al., 2020; Eratne et al., 2020a, 2020b).”
BackgroundResultInfluentialSelf-citationFittipaldi, S., Legaz, A., Maito, M., Hernandez, H., Altschuler, F., Canziani, V., Moguilner, S., Gillan, C. M., Castillo, J., Lillo, P., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00164-3 · Cited by 36
“…tasks of social cognition are increasingly used in research and clinical contexts to assess the performance of patients with age-related conditions such as subjective cognitive complaints (SCC), mild cognitive impairment (MCI) and dementia, in comparison to that of healthy controls (HCs) 9–11 .”
Self-citationKorb, M. K., Peck, A., Alfano, L. N., Berger, K. I., James, M. K., Ghoshal, N., Healzer, E., Henchcliffe, C., Khan, S., Mammen, P. P. A., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02172-5 · Cited by 37
“In the presence of such a history, bedside tests like the Montreal Cognitive Assessment (MoCA) can be used to approximate the level of cognitive impairment [35], but such tests do not provide sensitive screening tests for FTD.”
MethodSattler, R., Traynor, B. J., Robertson, J., Bosch, L. V. D., Barmada, S. J., Svendsen, C. N., Disney, M. D., Gendron, T. F., Wong, P. C., Turner, M. R., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00548-8 · Cited by 34
Self-citationKamalian, A., Khodadadifar, T., Saberi, A., Masoudi, M., Camilleri, J. A., Eickhoff, C. R., Zarei, M., Pasquini, L., Laird, A. R., Fox, P. T., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12318 · Cited by 31
“,major depressive disorder andbipolarmooddisorder), other forms of dementia or neurological symptoms, and no history of alcohol and substance abuse;3,18 (2) included at least six participants in either the patient or healthy group; (3) used VBM, fMRI (resting-state or task based), and FDG-PET as the imaging modality;…”
BackgroundMethodInfluentialSpotorno, N., Lindberg, O. E., Nilsson, C., Waldö, M. L., van Westen, D., Nilsson, K., Vestberg, S., Englund, E. M., Zetterberg, H., Blennow, K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236384 · Cited by 33
“constitute the main differential diagnosis for bvFTD (35).”
BackgroundSelf-citationLight, V., Jones, S. L., Rahme, E., Rousseau, K., de Boer, S., Vermunt, L., Soltaninejad, M., Teunissen, C. E., Pijnenburg, Y. A. L., Ducharme, S., et al. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.03.008 · Cited by 37
Self-citationNeurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates
Gallingani, C., Carbone, C., Tondelli, M., & Zamboni, G. (2024) · Brain Sciences · doi:10.3390/brainsci14030272 · Cited by 31
“The relevance of these findings has been included in a consensus paper of the Neuropsychiatric International Consortium for Frontotemporal Dementia (NIC-FTD), where NfLs have been proposed as a diagnostic biomarker to distinguish between bvFTD and PPDs [28].”
BackgroundWillemse, E. A. J., Scheltens, P., Teunissen, C. E., & Vijverberg, E. G. B. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00841-4 · Cited by 26
“Our results support sNfL as helpful biomarker for such clinical questions in particular [12, 17, 18].”
ResultSelf-citationIllán‐Gala, I., Falgàs, N., Friedberg, A., Castro‐Suárez, S., Keret, O., Rogers, N., Öz, D., Nigro, S. L., Quattrone, A., Quattrone, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.1290 · Cited by 27
Self-citationBruinsma, J., Peetoom, K. K. B., Boots, L. M. M., Daemen, M., Verhey, F. R. J., Bakker, C., & de Vugt, M. E. (2021) · Internet Interventions · doi:10.1016/j.invent.2021.100442 · Cited by 32
MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia
Manera, A. L., Dadar, M., Van Swieten, J. C., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce Jr, R., Graff, C., Synofzik, M., Galimberti, D., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-324106 · Cited by 23
Self-citationThe Psychiatric Misdiagnosis of Behavioral Variant Frontotemporal Dementia in a Colombian Sample
Zapata‐Restrepo, L. M., Rivas, J. C., Miranda, C., Miller, B. L., Ibáñez, A. M., Allen, I. E., & Possin, K. L. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.729381 · Cited by 29
Psychiatric symptoms of frontotemporal dementia and subcortical (co-)pathology burden: new insights
Scarioni, M., Gami‐Patel, P., Peeters, C. F. W., de Koning, F., Seelaar, H., Mol, M. O., Swieten, J. C. V., Bank, N. B., Rozemüller, A. J. M., Hoozemans, J. J. M., et al. (2022) · Brain · doi:10.1093/brain/awac043 · Cited by 27
“6,8 Among psychiatric symptoms of frontotemporal dementia, hallucinations have been reported in up to 17% of sporadic patients, although the lack of a formal inclusion criterion in the consensus clinical criteria may lead to an underestimate.”
Self-citationEratne, D., Keem, M. H., Lewis, C., Kang, M. J., Walterfang, M., Farrand, S., Loi, S. M., Kelso, W. M., Cadwallader, C. J., Berkovic, S. F., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120439 · Cited by 22
Self-citationBipolar disorder and frontotemporal dementia: A systematic review
Meller, M. R., Patel, S., Duarte, D. G. G., Kapczinski, F. P., & Cardoso, T. D. A. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13362 · Cited by 26
Recent Advances in Frontotemporal Dementia
Tartaglia, M. C., & Mackenzie, I. R. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.69 · Cited by 27
Franklin, H., Russell, L. L., Peakman, G., Greaves, C. V., Bocchetta, M., Nicholas, J. M., Poos, J. M., Convery, R. S., Cash, D. M., Swieten, J. C. V., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00865-w · Cited by 29
Self-citationFrontotemporal Dementia and Late-Onset Bipolar Disorder: The Many Directions of a Busy Road
da Silva, M. N. M., Porto, F. H. D. G., Lopes, P. M. G., Prado, C. S. D. C., Frota, N. A. F., Alves, C. H. L., & Alves, G. S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.768722 · Cited by 22
Hazelton, J. L., Carneiro, F., Maito, M., Richter, F., Legaz, A., Altschuler, F., Cubillos-Pinilla, L., Chen, Y., Doherty, C. P., Baez, S., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.10.013 · Cited by 21
Davy, V., Dumurgier, J., Fayossé, A., Paquet, C., & Cognat, E. (2021) · Diagnostics · doi:10.3390/diagnostics11050754 · Cited by 23
“This led international experts to recently publish consensus recommendations to distinguish bvFTD from PPD [5].”
BackgroundSajjadi, S. A., Bukhari, S. A., Scambray, K. A., Yan, R., Kawas, C. H., Montine, T. J., & Corrada, M. M. (2022) · Neurology · doi:10.1212/wnl.0000000000201345 · Cited by 21
“In addition, patients with FTD frequently demonstrate obsessive traits and anxiety.(31) Perry syndrome, a rare genetic form of TDP-43 pathologic change, also presents with apathy and atypical depression.”
BackgroundDegenerative dementias: Alterations of emotions and mood disorders
Mendez, M. F. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-822290-4.00012-8 · Cited by 24
Self-citationDiagnostic accuracy of research criteria for prodromal frontotemporal dementia
Benussi, A., Premi, E., Grassi, M., Alberici, A., Cantoni, V., Gazzina, S., Archetti, S., Gasparotti, R., Fumagalli, G., Bouzigues, A., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01383-1 · Cited by 21
“In the same view, considering neuropsychiatric symptoms in the framework of MCBMI [32] may possibly further improve its operational definition and neuropathological correlations.”
BackgroundSelf-citationBlood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review
Liampas, I., Kyriakoulopoulou, P., Karakoida, V., Kavvoura, P. A., Sgantzos, M. N., Bogdanos, D. P., Stamati, P., Dardiotis, E., & Siokas, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111838 · Cited by 25
Kang, M. J., Eratne, D., Dobson, H., Malpas, C. B., Keem, M. H., Lewis, C., Grewal, J. K., Tsoukra, V., Dang, C., Mocellin, R., et al. (2023) · Acta Neuropsychiatrica · doi:10.1017/neu.2023.25 · Cited by 17
“In particular, we saw that bvFTD was the most frequently changed diagnosis, further supporting the utility of biomarkers in this challenging diagnosis (Ducharme et al ., 2020).”
Self-citationAdvanced Magnetic Resonance Imaging for Early Diagnosis and Monitoring of Movement Disorders
Ortega‐Robles, E., Alonso, B. D. C., Cantillo-Negrete, J., Carino-Escobar, R. I., & Arias-Carrión, Ó. (2025) · Brain Sciences · doi:10.3390/brainsci15010079 · Cited by 26
“MRI often reveals frontal lobe atrophy in bvFTD, particularly affecting regions such as the anterior cingulate cortex and insula [128].”
Eratne, D., Kang, M. J., Malpas, C. B., Dang, C., Lewis, C., Bhalala, O. G., Li, Q.-X., Collins, S. J., Masters, C. L., Loi, S. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70717 · Cited by 24
“This could reflect issues previously described with NfL technical/analytical/reference range issues 10,42 or, more likely, highlights greater complexity and clinical and biomarker heterogeneity, seen in bvFTD. 43 percentile,wouldbothbeclassifiedas“low”).”
Self-citationVentricular features as reliable differentiators between bvFTD and other dementias
Manera, A. L., Dadar, M., Collins, D. L., & Ducharme, S. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102947 · Cited by 23
“MoCA 28[25-29] 19[12-23] 21[17-22] 21[10-25] 26[25-28] 23[2126] 19[14-21] <0.”
BackgroundSelf-citationDelaby, C., Ladang, A., Martinez‐Yriarte, J., Zecca, C., Logroscino, G., Körtvelyessy, P., Tumani, H., Parchi, P., Quadrio, I., Hart, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70343 · Cited by 22
Self-citationTomasello, L., Carlucci, L., Laganà, A., Galletta, S., Marinelli, C. V., Raffaele, M., & Zoccolotti, P. (2023) · Brain Sciences · doi:10.3390/brainsci13060930 · Cited by 24
“Following the test manual, scores between 25 and 30 points indicated early and mild stages [35].”
MethodBlood level of neurofilament light chain as a biomarker for neurological disorders
Turner, M. R., Thompson, A. G., & Teunissen, C. E. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2024-000958 · Cited by 27
“…an important application in primary psychiatric disorders versus neurological disorders with psychiatric features, such as frontotemporal dementia 24 or Creutzfeldt-Jakob disease, with substantially increased levels prompting consideration of both primary brain parenchymal disease and adverse…”
Eratne, D., Kang, M. J., Lewis, C. C., Dang, C., Malpas, C. B., Ooi, S., Brodtmann, A. G., Darby, D., Zetterberg, H., Blennow, K., et al. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123291 · Cited by 23
“Timely and accurate diagnosis of behavioural variant frontotemporal dementia (bvFTD) remains a common challenge, especially when distinguishing from primary psychiatric conditions [1,2].”
Self-citationProgressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses
Dang, J., Graff‐Radford, J., Duffy, J. R., Utianski, R. L., Clark, H. M., Stierwalt, J. A. G., Whitwell, J. L., Josephs, K. A., & Botha, H. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10585-8 · Cited by 20
Living With Frontotemporal Degeneration: Diagnostic Journey, Symptom Experiences, and Disease Impact
Barker, M. S., Dodge, S. G., Niehoff, D., Denny, S., Dacks, P. A., Dickinson, S., Cosentino, S., & Wheaton, D. K. H. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221119976 · Cited by 17
“The main points of branching were based on whether the respondent was (1) an individual diagnosed with FTD, (2) a biological relative of someone diagnosed who is not a care partner, (3) deemed to be at biological risk of developing FTD, (4) a current care partner of someone diagnosed with FTD, or (5) a past care partn…”
BackgroundFrontotemporal dementia. How to deal with its diagnostic complexity?
Antonioni, A., Raho, E. M., Granieri, E., & Koch, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461758 · Cited by 25
“Nonetheless, as recently suggested, with the exception of certain genetic cases where hypometabolic patterns may not always match expected findings, FDG-PET can generally aid in ruling out bvFTD when results are normal [100,393].”
InfluentialFrontotemporal dementia subtyping using machine learning, multivariate statistics and neuroimaging
Metz, A., Zeighami, Y., Ducharme, S., Villeneuve, S., & Dadar, M. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf065 · Cited by 22
“…the results of the PLS analysis onto the longitudinal data of the same cohort as an in-sample validation (with subject-level cross-validation), our maximal classification model achieved an accuracy of 88.09% and our minimal model was 85.77% accurate, suggesting reliability of both classifiers.”
InfluentialSelf-citationIdentifying and Diagnosing TDP-43 Neurodegenerative Diseases in Psychiatry
Ducharme, S., Pijnenburg, Y. A. L., Rohrer, J. D., Huey, E. D., Finger, E. C., & Tatton, N. A. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.017 · Cited by 22
“Genetic testing may be warranted in any patient with unexplained late-onset behavioral disturbance (particularly psychosis) who has a first-degree relative with ALS or FTD. 6,115 LATE LATE-NC presents in older patients with short-term recall deficits and is frequently mixed with other pathologies, sometimes accompanie…”
BackgroundInfluentialSelf-citationQuispialaya, K. M., Therriault, J., Aliaga, A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Macedo, A. C., Rahmouni, N., Tissot, C., Arias, J. F., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210211 · Cited by 19
den Stock, J. V., Bertoux, M., Diehl‐Schmid, J., Piguet, O., Rankin, K. P., Pasquier, F., Ducharme, S., Pijnenburg, Y. A. L., & Kumfor, F. (2022) · Neuropsychology Review · doi:10.1007/s11065-022-09554-3 · Cited by 17
Self-citationPractice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders)
Kato, T., Ogasawara, K., Motomura, K., Kato, M., Tanaka, T., Takaesu, Y., Nio, S., Kishi, T., So, M., Nemoto, K., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13724 · Cited by 20
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Perna, A., Montine, K. S., White, L. R., Montine, T. J., & Cholerton, B. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01441-w · Cited by 16
Diagnostic Instability Over Time in the Late-Onset Frontal Lobe Syndrome: When Can We Say it's FTD?
de Boer, S. C. M., Gossink, F., Krudop, W., Vijverberg, E., Schouws, S., Reus, L. M., Pijnenburg, Y. A. L., & Dols, A. (2023) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.02.006 · Cited by 15
Self-citationHenríquez, F., Cabello, V., Báez, S., de Souza, L. C., Lillo, P., Martínez‐Pernía, D., Olavarría, L., Torralva, T., & Slachevsky, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.768591 · Cited by 18
Self-citationA narrative review on mild behavioural impairment: an exploration into its scientific perspectives
Cozza, M., & Boccardi, V. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02472-1 · Cited by 18
“Screening for the C9orf72 mutation is necessary in all possible/probable cases of bvFTD and suspected psychiatric cases that do not meet FTD criteria [20].”
BackgroundPET Imaging in Psychiatric Disorders
Ferrando, R., Hernandes, D., Ghini, B. G., & Coutinho, A. M. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.004 · Cited by 20
Kumfor, F., Liang, C. T., Hazelton, J. L., Leyton, C. E., Kaizik, C., Devenney, E. M., Connaughton, E., Langdon, R. A., Mioshi, E., Kwok, J. B., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5692 · Cited by 15
“The high presence of delusions likely contributes to the ∼50% of bvFTD patients who are initially diagnosed with a primary psychiatric disorder.(3,38) Interestingly some evidence suggests that patients clinically diagnosed with FTD are more likely to”
BackgroundSelf-citationHazelton, J. L., Della Bella, G., Barttfeld, P., Dottori, M., Gonzalez-Gomez, R., Migeot, J., Moguilner, S., Legaz, A., Hernandez, H., Prado, P., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105614 · Cited by 14
“93 Altered intrinsic neural timescales measured by the ACW are observed in psychiatric conditions during resting state and self-referential processing.”
Self-citationDas, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01409-8 · Cited by 12
“…of the AD biomarkers amyloid-beta42, total tau, and phosphorylated tau181 to determine positive or negative AD biomarkers status (cutoffs applied as published elsewhere), electroencephalography and neuro- imaging-magnetic resonance imaging, and, if indicated, a [ 18 F]FDG-PET scan [3, 30].”
BackgroundMethodInfluentialSelf-citationAntonioni, A., Raho, E. M., Spampinato, D. A., Granieri, E., Fadiga, L., Lorenzo, F. D., & Koch, G. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106194 · Cited by 20
“…FTD often affects younger patients in comparison to the other neurodegenerative dementias (i.e. AD and dementia with Lewy bodies, DLB), diagnostic delays and misdiagnoses are frequent (Ducharme et al., 2020), preventing adequate and early care and therapeutic management (Besser and Galvin, 2020).”
Frontotemporal dementia: A unique window on the functional role of the temporal lobes
Borghesani, V., Deleon, J., & Gorno‐Tempini, M. L. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823493-8.00011-0 · Cited by 17
Plasma proteome profiling identifies changes associated to AD but not to FTD
Mofrad, R. B., del Campo, M., Peeters, C. F. W., Meeter, L. H. H., Seelaar, H., Simmelink, M. J. A., Ramakers, I. H. G. B., Middelkoop, H. A. M., Deyn, P. P. D., Claassen, J. A. H. R., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01458-w · Cited by 13
Self-citationSeritan, A. L. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231164357 · Cited by 15
“64 Psychotic symptoms occur late in the course of PD and may arise in cognitively intact people, not just those with major NCD. 66-68 Minor psychotic phenomena include auditory or visual illusions, passage hallucinations (brief visions of a person or animal passing in the periphery of the visual fi eld), and extracampi…”
InfluentialClark, D. G. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001506 · Cited by 16
Social cognition assessment for mild neurocognitive disorders
den Stock, J. V. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12475 · Cited by 11
Self-citationAssogna, M., Sprugnoli, G., Press, D. Z., Dickerson, B. C., Macone, J., Bonnì, S., Borghi, I., Connor, A., Hoffman, M., Grover, N., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12219 · Cited by 14
Biological basis and psychiatric symptoms in frontotemporal dementia
Mori, K., & Ikeda, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13375 · Cited by 13
“Current recommendation includes C9orf72 screening in all cases with possible or probable bvFTD, regardless of family history.(105) Patients with FTLDTDP (especially type A and B) developed psychosis significantly more frequently in comparison to patients with FTLD-tau and AD in the first 3 years after clinical disease…”
BackgroundResultInfluentialSelf-citationvan Engelen, M. E., Verfaillie, S. C. J., Dols, A., Oudega, M. L., Boellaard, R., Golla, S. S. V., den Hollander, M. E., Ossenkoppele, R., Scheltens, P., van Berckel, B. N. M., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01020-2 · Cited by 14
“In the absence of an accurate specific molecular biomarker for bvFTD, the disease is particularly difficult to distinguish from primary psychiatric disorders (PPD), such as late-onset bipolar disorder, autism spectrum disorder, personality disorders, schizophrenia and major depressive disorders, due to significant ove…”
BackgroundSelf-citationPrevalence and Features of Misdiagnosis of Primary Psychiatric Disorders Among bvFTD Patients
Mukwikwi, E.-R., Jones, S. L., Manera, A. L., Salpeter, R., Fumagalli, G., Eratne, D., Kang, M. J., Bertoux, M., Didic, M., Katisko, K., et al. (2025) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20240238 · Cited by 12
Self-citationCCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment
Brisson, M., Brodeur, C., Guillon, L. L., Masellis, M., Stoessl, A. J., Tamm, A., Zukotynski, K., Ismail, Z., Gauthier, S. G., Rosa‐Neto, P., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12098 · Cited by 11
Self-citationRuggeri, M., Ricci, M., Gerace, C., & Blundo, C. (2021) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2021.1996342 · Cited by 12
Morrow, C. B., Kamath, V. J., Dickerson, B. C., Eldaief, M. C., Rezaii, N., Wong, B., McGinnis, S. M., Darby, R., Staffaroni, A. M., Lapid, M. I., et al. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13810 · Cited by 14
Self-citationWatanabe, R. G. S., Knochenhauer, A. E., Fabrin, M. A., Siqueira, H. H., Martins, H. F., Mello, C. D. D. O., Zingano, B. D. L., Botelho, M. F., Yacubian, E. M. T., Filho, G. R. D. O., et al. (2021) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2021.1941830 · Cited by 12
“…disease (d = 1.29) and, healthy controls (d = 1.79) and ToM assessment could constitute an early identification, although not a diagnostic criterion (Bora et al., 2015; Johnen & Bertoux, 2019), there is a clinical recommendation for social cognition testing in bvFTD (Ducharme et al., 2020).”
BackgroundInfluential
Metadata
- Authors
- Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., Huey, E., Vandenbulcke, M., Masellis, M., Trieu, C., Onyike, C., Caramelli, P., de Souza, L. C., Santillo, A., Waldö, M. L., Landin-Romero, R., Piguet, O., Kelso, W., Eratne, D., Velakoulis, D., Ikeda, M., Perry, D., Pressman, P., Boeve, B., Vandenberghe, R., Mendez, M., Azuar, C., Levy, R., Le Ber, I., Baez, S., Lerner, A., Ellajosyula, R., Pasquier, F., Galimberti, D., Scarpini, E., van Swieten, J., Hornberger, M., Rosen, H., Hodges, J., Diehl-Schmid, J., & Pijnenburg, Y.
- Affiliations
- Montreal Neurological Institute and Hospital (CA)
- Amsterdam Neuroscience (NL)
- Université Laval (CA)
- The University of Sydney (AU)
- Laboratory for Translational Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium
- CERVO brain Research Centre, Laval University, Quebec, Canada
- Erasmus MC (NL)
- Columbia University (US)
- Universitair Ziekenhuis Leuven (BE)
- Sunnybrook Health Science Centre (CA)
- Johns Hopkins University (US)
- Universidade Federal de Minas Gerais (BR)
- Behavioral and Cognitive Neurology Research Group, Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Lund University (SE)
- Brain and Mind Centre, University of Sydney, Sydney, Australia
- The Royal Melbourne Hospital (AU)
- The University of Osaka (JP)
- University of California, San Francisco (US)
- University of Colorado Denver (US)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Pitié-Salpêtrière Hospital (FR)
- Department of Neurology, Hôpital La Pitié Salpêtrière, Paris, France
- Department of Psychology, Andes University, Bogota, Colombia
- University Hospitals of Cleveland (US)
- Manipal Hospital (IN)
- Inserm (FR)
- University of Milan (IT)
- Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
- Department of Medicine, Norwich Medical School, Norwich, UK
- Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany
- Corresponding author
- Ducharme, Simon
- ORCID
- Ducharme, Simon
- Dols, Annemiek
- Laforce, Robert
- Devenney, Emma
- Kumfor, Fiona
- van den Stock, Jan
- Seelaar, Harro
- Gossink, Flora
- Vijverberg, Everard
- Huey, Edward
- Vandenbulcke, Mathieu
- Masellis, Mario
- Trieu, Calvin
- Onyike, Chiadi
- Caramelli, Paulo
- Santillo, Alexander
- Waldö, Maria Landqvist
- Landin-Romero, Ramon
- Piguet, Olivier
- Kelso, Wendy
- Eratne, Dhamidhu
- Velakoulis, Dennis
- Ikeda, Manabu
- Perry, David
- Pressman, Peter
- Boeve, Bradley
- Vandenberghe, Rik
- Mendez, Mario
- Lerner, Alan
- Ellajosyula, Ratnavalli
- Pasquier, Florence
- Galimberti, Daniela
- Scarpini, Elio
- Hornberger, Michael
- Rosen, Howard
- Hodges, John
- Pijnenburg, Yolande
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-04
- Volume
- 143
- Issue
- 6
- Pages
- 1632-1650
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC7849953
- OpenAlex
- W3009452141
- Cited by
- 320
- References
- 202
- Citations by year
- 2026: 39 · 2025: 53 · 2024: 64 · 2023: 56 · 2022: 57 · 2021: 43 · 2020: 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Lirias (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Fond de Recherche du Québec–Santé
- NIH
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- behavioral variant frontotemporal dementia, differential diagnosis, mental illness, delayed diagnosis, clinical evaluation, FDG-PET, neurofilament light chain, neuropsychological assessment
- MeSH terms
- Mental Disorders, Diagnosis, Differential, Female, Humans, Magnetic Resonance Imaging, Male, Neurologic Examination, Neuropsychological Tests, Fluorodeoxyglucose F18, Positron-Emission Tomography, Frontotemporal Dementia, Delayed Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.